Strategic Partnerships Recent and notable partnerships with Cardinal Health, ESBE Scientific, Rockland Immunochemicals, and expansion into Canada highlight DBS's strong distributor and geographic growth potential. This creates opportunities to pursue co-selling, co-marketing, and refurbished or exclusive distribution deals in new and existing territories.

Global Expansion New office presence in Canada and ongoing global outreach suggest demand across regions for IHC reagents and custom antibody services. Target hospitals, CROs, and academic centers in North America and beyond with region-specific campaigns and localized regulatory support packages.

Comprehensive IHC Portfolio DBS offers monoclonal and polyclonal antibodies, diverse detection systems, and custom antibody production services, including peptide synthesis and conjugation. Leverage this breadth to upsell bundled reagent kits, validation panels, and end-to-end IHC solutions to pathology labs and research labs seeking single-vendor efficiency.

Regulatory & Quality Advantage FDA registered medical device manufacturer with ISO 9001:2008 and CE-marked devices positions DBS as a compliant supplier for regulated labs. Market to quality-conscious customers with emphasis on reliability, traceability, and QMS-backed performance for clinical and translational research settings.

Growth Revenue Signals Reported revenue in the mid-range of tens of millions indicates a scalable mid-market footprint. This suggests opportunities for expanders such as recurring reagent replenishment programs, subscription-style ordering for antibodies and detection systems, and tiered pricing for high-volume customers.